{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-071370","form_type":"8-K","ticker":"ELDN","cik":"0001404281","company_name":"Eledon Pharmaceuticals, Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.179999+00:00","generated_at":"2026-05-21T08:14:36.122568+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Eledon Q1 net loss $6.5M; cash $124.9M; on track for BESTOW topline in Q4","bullets":["Net loss of $6.5M ($0.08/share) vs $23.6M loss in Q1 2024; adjusted net loss $16.6M vs $10.3M.","Cash, equivalents and short-term investments $124.9M as of March 31, 2025; funds operations to end of 2026.","R&D expenses $13.5M (incl. $1.0M SBC) vs $7.4M prior year; G&A $4.4M vs $3.5M.","Tegoprubart used in second genetically modified pig kidney transplant at Mass General; patient discharged without dialysis.","Topline Phase 2 BESTOW results on track for Q4 2025; interim Phase 1b data expected August 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-071370","json":"https://secwatch.observer/filing/0000950170-25-071370.json","markdown":"https://secwatch.observer/filing/0000950170-25-071370.md","text":"https://secwatch.observer/filing/0000950170-25-071370.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404281/000095017025071370/0000950170-25-071370-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404281/000095017025071370/eldn-20250514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T08:14:36.122568+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}